<DOC>
	<DOC>NCT02238366</DOC>
	<brief_summary>The purpose of this study is to collect some parameters which may help to provide guidance on how Androgen Deprivation Therapy (ADT) drugs are renewed and physician satisfaction.</brief_summary>
	<brief_title>Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Adult men, â‰¥18 years old, with recently diagnosed locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy as monotherapy or as concomitant and adjuvant therapy in association with radiation therapy, with a 1 or 3 month GnRH analogue triptorelin formulation Expected survival &gt; 12 months. Patients having provided written informed consent. Patients mentally fit for completing a questionnaire. Treatment with any investigational drug within the last 3 months before study entry or planning to participate in a study. Patients who already have been treated with a GnRH analogue within the last year. Patients with hypersensitivity to GnRH, GnRH analogue, triptorelin or its excipients. Patients with a contraindication according to SmPC.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>